HF 81

1st Engrossment - 92nd Legislature (2021 - 2022) Posted on 03/23/2022 12:26pm

A bill for an act
relating to health; requesting the Minnesota Board of Pharmacy to establish
pharmacogenomics (PGx) task force; requiring a report; appropriating money.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1. new text begin PHARMACOGENOMICS (PGX) TASK FORCE.
new text end

new text begin Subdivision 1. new text end

new text begin Establishment. new text end

new text begin The Minnesota Board of Pharmacy shall establish a
pharmacogenomics (PGx) task force to evaluate and assess the current availability of
pharmacogenomics statewide and to develop recommendations for making
pharmacogenomics available statewide. For purposes of this section, "pharmacogenomics"
means the determination of how variation in an individual's genomic information influences
medication safety and efficacy.
new text end

new text begin Subd. 2. new text end

new text begin Membership. new text end

new text begin (a) The PGx task force shall consist of members appointed by
the executive director of the Minnesota Board of Pharmacy according to paragraph (c) and
four members of the legislature appointed according to paragraph (e).
new text end

new text begin (b) The task force will elect a chair and co-chair and other officers as the members deem
necessary.
new text end

new text begin (c) The executive director shall appoint the following members:
new text end

new text begin (1) at least two pharmacists with expertise in pharmacogenomics from the University
of Minnesota;
new text end

new text begin (2) at least two other pharmacists licensed and practicing within the state with expertise
in pharmacogenomics;
new text end

new text begin (3) at least two physicians licensed and practicing in the state;
new text end

new text begin (4) at least two health system or clinic administrators, or their designees, from the state;
new text end

new text begin (5) a representative of a patient organization that operates in the state;
new text end

new text begin (6) a patient or caregiver with an interest in pharmacogenomics;
new text end

new text begin (7) a pharmacist or other provider who is a member of a diverse and underrepresented
community;
new text end

new text begin (8) a second member of a diverse and underrepresented community;
new text end

new text begin (9) a representative of the biotechnology industry;
new text end

new text begin (10) a representative of payers, health plans, or insurers;
new text end

new text begin (11) an expert in health informatics from the University of Minnesota;
new text end

new text begin (12) an expert in data management and security;
new text end

new text begin (13) an expert in ethical, legal, and social implications of genomics;
new text end

new text begin (14) an expert in health regulatory affairs from the state; and
new text end

new text begin (15) a genetic counselor.
new text end

new text begin (d) Members appointed according to paragraph (c) shall reflect an equitable statewide
geographical representation and representation from diverse groups within the state.
new text end

new text begin (e) The PGx task force shall include two members of the senate, one appointed by the
majority leader and one appointed by the minority leader, and two members of the house
of representatives, one appointed by the speaker of the house and one appointed by the
minority leader.
new text end

new text begin (f) The executive director or a designee shall serve as an ex officio, nonvoting member
of the PGx task force.
new text end

new text begin (g) Initial appointments to the PGx task force shall be made no later than September 1,
2021. Members appointed according to paragraph (c) shall serve for a term of one year.
new text end

new text begin Subd. 3. new text end

new text begin Meetings. new text end

new text begin The first meeting of the PGx task force shall be convened no later
than October 1, 2021. The PGx task force shall meet at the call of the chairperson or at the
request of a majority of PGx task force members.
new text end

new text begin Subd. 4. new text end

new text begin Duties. new text end

new text begin The PGx task force's duties may include but are not limited to:
new text end

new text begin (1) conducting a comprehensive analysis of strategies that could be undertaken to
implement pharmacogenomics across the state;
new text end

new text begin (2) determining what education in pharmacogenomics is needed by the health care
workforce to improve effectiveness of and reduce adverse reactions to medications through
the use of pharmacogenomics;
new text end

new text begin (3) soliciting input from the public on readiness for adoption of pharmacogenomics;
new text end

new text begin (4) considering the needs and perspectives of diverse and underrepresented communities;
and
new text end

new text begin (5) developing recommendations for:
new text end

new text begin (i) diffusion of pharmacogenomics services into practice across the state;
new text end

new text begin (ii) necessary education for providers;
new text end

new text begin (iii) evaluation of the benefits and value to health of pharmacogenomics; and
new text end

new text begin (iv) building capacity for research on pharmacogenomics needs and capabilities across
the state.
new text end

new text begin Subd. 5. new text end

new text begin Contracts. new text end

new text begin The Board of Pharmacy may enter into a contract with the University
of Minnesota for conducting research and surveys, or providing administrative assistance
to the task force.
new text end

new text begin Subd. 6. new text end

new text begin Conflict of interest. new text end

new text begin PGx task force members are subject to state policy on
conflicts of interest.
new text end

new text begin Subd. 7. new text end

new text begin Report required. new text end

new text begin By June 30, 2022, the executive director shall report to the
chairs and ranking minority members of the legislative committees with jurisdiction over
health care policy on the activities of the PGx task force. At a minimum, the report must
include:
new text end

new text begin (1) a description of the PGx task force's goals; and
new text end

new text begin (2) a description of the independent recommendations made by the PGx task force.
new text end

new text begin Subd. 8. new text end

new text begin Expiration. new text end

new text begin The PGx task force expires September 1, 2022.
new text end

Sec. 2. new text begin APPROPRIATION.
new text end

new text begin $250,000 in fiscal year 2022 is appropriated from the general fund to the Minnesota
Board of Pharmacy for the pharmacogenomics (PGx) task force under section 1. This is a
onetime appropriation. This appropriation is available until expended.
new text end